BioVie Secures All Scientific Approvals Needed to Receive Additional 12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID
BIVI Stock | USD 2.70 0.06 2.17% |
Under 74% of Biovie's investor base is looking to short. The analysis of the overall investor sentiment regarding Biovie Inc suggests that many traders are alarmed. Biovie's investing sentiment shows overall attitude of investors towards Biovie Inc.
Biovie |
Approval from U.S. Army Medical Research and Development Command, Office of Human Research Oversight is the last scientific milestone needed for Company to receivebulk of 13.1 million grant funding Company anticipates Phase 2 trial to commence by early 2025 CARSON CITY, Nev., Sept. 16, 2024 -- BioVie Inc. , , a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders an
Read at finance.yahoo.com
Biovie Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Biovie can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Biovie Fundamental Analysis
We analyze Biovie's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biovie using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biovie based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Biovie is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Biovie Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biovie stock to make a market-neutral strategy. Peer analysis of Biovie could also be used in its relative valuation, which is a method of valuing Biovie by comparing valuation metrics with similar companies.
Peers
Biovie Related Equities
XFOR | X4 Pharmaceuticals | 13.43 | ||||
ABOS | Acumen Pharmaceuticals | 0.46 | ||||
MREO | Mereo BioPharma | 0.26 | ||||
DAWN | Day One | 0.45 | ||||
INZY | Inozyme Pharma | 0.67 | ||||
AMLX | Amylyx Pharmaceuticals | 3.10 | ||||
ELDN | Eledon Pharmaceuticals | 3.11 | ||||
TERN | Terns Pharmaceuticals | 3.18 | ||||
HOOK | Hookipa Pharma | 7.88 |
Complementary Tools for Biovie Stock analysis
When running Biovie's price analysis, check to measure Biovie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biovie is operating at the current time. Most of Biovie's value examination focuses on studying past and present price action to predict the probability of Biovie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biovie's price. Additionally, you may evaluate how the addition of Biovie to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |